Microfluidics in heart-on-a-chip platforms for cardiovascular drug discovery and cardiotoxicity assessment
Advanced Drug Delivery Reviews · 2026-12 · 239 · 115972
DOI: 10.1016/j.addr.2026.115972 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026-12. Verfasst von Caner Dikyol und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Engineering, University of Toronto, Toronto, ON, Canada; Toronto General Hospital Research Institute, University Health Netwo…. Hauptthemen laut MEDLINE: Drug Discovery, Cardiotoxicity, Lab-On-A-Chip Devices, Microfluidics. Die Arbeit nennt 153 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada, National Institutes of Health, Heart and Stroke Foundation of Canada.
Abstract (Originalsprache)
Cardiovascular disease remains the leading cause of death worldwide. The limited translational fidelity of traditional preclinical models continues to constrain the development of safer and more effective therapies. Animal studies and static two-dimensional cultures only partially reproduce human cardiac physiology, including mechanical loading, perfusion, multicellular interactions, and drug metabolism, which contribute to late-stage failure and unexpected cardiotoxicity. Accordingly, there is a growing need for human-relevant platforms that can more accurately model cardiac (patho)physiology, support drug discovery, and improve safety assessment. Microfluidic heart-on-a-chip (HoC) systems address this need by combining microfabrication, tissue engineering, and controlled fluid flow to generate miniaturized cardiac tissues with physiologically relevant biochemical, mechanical, and electrical cues. These platforms can provide real-time functional readouts, including contractility, electrophysiology, calcium handling, metabolic activity, and biomarker release, while also enabling the study of disease-relevant phenotypes such as ischemia-reperfusion injury, arrhythmias, fibrosis, and cardiomyopathy. In addition, HoC systems are increasingly being integrated with biosensors, automation, and multi-organ configurations to capture drug metabolism and inter-organ crosstalk, further improving their predictive value for efficacy and toxicity screening. In this review, we summarize the core design elements of microfluidic HoC platforms, highlight their applications in cardiovascular drug discovery and cardiotoxicity assessment, and discuss current challenges and future directions for the field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biomedical Engineering, University of Toronto, Toronto, ON, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada; Terrence Donnelly Centre for Cellular and Bio…
- Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, ON, Canada; Acceleration Consortium, University of Toronto, Toronto, Canada.
Förderung
- Natural Sciences and Engineering Research Council of Canada
- National Institutes of Health
- Heart and Stroke Foundation of Canada
- CIHR
- Additional Ventures
Zitieren
APA
Dikyol, C., Alsaafin, A., Bodenstein, D. F., Beeghly, G. F., Popovic, A. M., Jiang, R., & Radisic, M. (2026). Microfluidics in heart-on-a-chip platforms for cardiovascular drug discovery and cardiotoxicity assessment. Advanced Drug Delivery Reviews, 239, 115972. https://doi.org/10.1016/j.addr.2026.115972
Vancouver
Dikyol C, Alsaafin A, Bodenstein DF, Beeghly GF, Popovic AM, Jiang R, et al. Microfluidics in heart-on-a-chip platforms for cardiovascular drug discovery and cardiotoxicity assessment. Advanced Drug Delivery Reviews. 2026;239:115972. doi:10.1016/j.addr.2026.115972
BibTeX
@article{Dikyol2026,
author = {Dikyol, Caner and Alsaafin, Alaa and Bodenstein, David F and Beeghly, Garrett F and Popovic, Anna Maria and Jiang, Richard and Radisic, Milica},
title = {Microfluidics in heart-on-a-chip platforms for cardiovascular drug discovery and cardiotoxicity assessment},
journal = {Advanced Drug Delivery Reviews},
year = {2026},
volume = {239},
pages = {115972},
doi = {10.1016/j.addr.2026.115972}
}
EUVIMED